The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis

Oncotarget
Min YuZhixiang Jian

Abstract

Increased glycolysis is one of the hallmarks of cancer. The abnormal expression of glucose transporter 1 (GLUT1) was reported to be associated with resistance to current therapy and poor prognosis. Numerous studies have investigated the correlation between GLUT1 expression and prognosis in cancers, but the conclusions are still controversial. Here, we conducted a meta-analysis to explore the association between GLUT1 and survival in human cancers. PubMed, Springer, Medline, and Cochrane Library were searched carefully to identify eligible studies evaluating prognostic value of GLUT1 in cancers. Twenty-seven studies with 4079 patients were included in the present study. Our pooled results identified that increased expression of GLUT1 was associated with unfavorable overall survival (HR = 1.780, 95% CI = 1.574-.013, p < 0.001)) and poorer disease-free survival (HR = 1.95, 95% CI = 1.229-3.095, p = 0.003). Furthermore, overexpression of GLUT1 linked with poor differentiated tumors (RR = 1.380, 95% CI = 1.086-1.755, p = 0.009; I2 = 72.0%, p < 0.001), positive lymph node metastasis (RR = 1.395, 95% CI = 1.082-1.799, p = 0.010; I2 = 70.8%, p = 0.002) and larger tumor size (RR = 1.405, 95% CI = 1.231-1.603, p < 0.001; I2 = 37.3%, p = ...Continue Reading

References

Mar 8, 2002·American Journal of Physiology. Endocrinology and Metabolism·Hans-Georg JoostBernard Thorens
Oct 31, 2002·Statistics in Medicine·Paula R WilliamsonAnthony G Marson
Nov 6, 2002·Japanese Journal of Cancer Research : Gann·Sung Soo KangYong Koo Park
Jan 31, 2004·Gynecologic Oncology·Valeria SebastianiPiero Luigi Alo
Mar 17, 2009·The American Journal of Pathology·Thomas AmannClaus Hellerbrand
Jul 17, 2009·Scandinavian Journal of Gastroenterology·Mateja LeganVera Ferlan Marolt
Oct 13, 2009·Pathology, Research and Practice·Ji-Youn SungYoun Wha Kim
Nov 16, 2010·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Sigve AndersenRoy M Bremnes
Sep 19, 2012·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Ji Eun KwonJa Seung Koo
Dec 12, 2012·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·Makoto ShimanishiHiroyoshi Hiratsuka
Dec 26, 2012·Biochimica Et Biophysica Acta·Leszek Szablewski
Jan 12, 2013·Virchows Archiv : an International Journal of Pathology·Pramila RamaniMargaret T May
Mar 20, 2013·Molecular Aspects of Medicine·Mike Mueckler, Bernard Thorens
Sep 12, 2013·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Shengjiao LiXing Ran
Apr 8, 2014·Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology·Martin GrimmSiegmar Reinert
Nov 22, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Katarzyna StarskaAnna Krześlak
Feb 27, 2015·PloS One·Min YuRufu Chen
Apr 4, 2015·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Jun OsugiMitsukazu Gotoh
Jan 11, 2016·Medical Oncology·Jianhong ZuoGebo Wen

❮ Previous
Next ❯

Citations

Jun 5, 2019·International Journal of Molecular Sciences·Terézia Kisková, Monika Kassayová
Dec 22, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Barbara Juraszek, Katarzyna A Nałęcz
Dec 5, 2019·Arquivos De Gastroenterologia·Juliana Vanessa Colombo Martins-PerlesJacqueline Nelisis Zanoni
Nov 2, 2019·Oncotarget·Bahir H ChamseddinRichard C Wang
May 3, 2018·Oncotarget·Jaine K BlayneyUNKNOWN Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Study Group
Nov 7, 2017·The Prostate·Hengjun XiaoJun Chen
Jan 15, 2020·Prostate Cancer and Prostatic Diseases·Salma MeziouFrédéric Pouliot
Aug 11, 2020·Molecular Oncology·Elisabeth SmolleKatharina Leithner
Aug 19, 2020·The FEBS Journal·Mattia D PizzagalliGiulio Superti-Furga
Sep 2, 2020·The Journal of Clinical Investigation·Ellen C de HeerAdrian L Harris
Apr 23, 2020·Frontiers in Oncology·Ilias Georgakopoulos-SoaresApostolos Zaravinos
Aug 14, 2019·Cancers·Aditi SharmaMala Shanmugam
Aug 23, 2020·Cancers·Kanchan VishnoiBasabi Rana
Jul 22, 2019·International Journal of Molecular Sciences·Angara ZambranoMónica Salas
Nov 22, 2017·International Journal of Cancer. Journal International Du Cancer·Pedro Gonzalez-MenendezRosa M Sainz
Dec 22, 2020·Genetic Testing and Molecular Biomarkers·Yujun GuGanbin Qiu
Jul 2, 2019·Journal of Pediatric Gastroenterology and Nutrition·Chantal Florence MeierRaphael Nicolas Vuille-Dit-Bille
Jan 19, 2020·Nature Reviews. Urology·Julieta AfonsoFátima Baltazar
Nov 17, 2020·Frontiers in Cell and Developmental Biology·Katarzyna A Nałęcz
Jun 12, 2020·Journal of Clinical Biochemistry and Nutrition·Nosayba Al-Azzam
Mar 14, 2019·Arhiv za higijenu rada i toksikologiju·Ivana Vrhovac MadunićIvan Sabolić
Jul 10, 2021·Cellular & Molecular Immunology·Bradley I ReinfeldJeffrey C Rathmell
Aug 28, 2021·Cancers·Monika Pliszka, Leszek Szablewski
Aug 28, 2021·Biomolecules·Heinrich BothaAntonio Celentano
Sep 24, 2021·Cancer Control : Journal of the Moffitt Cancer Center·Karolina KozalAnna Krześlak
Oct 22, 2021·Frontiers in Endocrinology·Theresa QuintingTimm Schreiber

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
biopsy

Software Mentioned

Stata

Related Concepts

Related Feeds

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Cancer Metabolic Reprogramming (Keystone)

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.